DOJ & DEA Take Action Against Manufactured Opioid Compounds

This week, the U.S. Department of Justice announced important federal action targeting manufactured and concentrated opioid compounds associated with 7-OH, while specifically distinguishing these products from traditional botanical kratom.

The Drug Enforcement Administration is temporarily placing mitragynine pseudoindoxyl (MGPI), MGM-15, and MGM-16 into Schedule I. Importantly, DOJ made clear that this action is directed at deliberately manufactured and concentrated opioid products & NOT traditional botanical kratom.

This distinction is exactly what the AKA has been fighting to make clear to policymakers across the country: natural kratom leaf should not be punished because of dangerous, chemically manipulated products being marketed as “kratom.”

👉 READ THE AKA PRESS RELEASE